Anrotinib, a targeted drug developed independently in China, is a multikinase inhibitor, mainly used in the treatment of small cell lung cancer and many kinds of sarcomas. Anrotinib is a multi-target receptor tyrosine kinase (RTK) inhibitor. It can inhibit the proliferation of a variety of tumor cell lines, and is clinically indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed or relapsed after receiving at least 2 prior systemic chemotherapies, as well as patients with small cell lung cancer who have progressed or relapsed after receiving at least 2 prior chemotherapy regimens. Anrotinib also has a controlling effect on a variety of sarcomas and is currently used in the treatment of a variety of malignancies, such as vesicular soft tissue sarcoma, clear cell sarcoma, and other advanced soft tissue sarcomas that have progressed or relapsed after at least 2 prior anthracycline-containing chemotherapy regimens. Anrotinib is indicated for use in several age groups, but adverse reactions such as bleeding, thrombosis, interstitial lung disease, and pneumothorax may occur during administration and should be used under medical supervision. It should be contraindicated for those who are allergic to any of the components of the product, for patients with central squamous lung cancer or those with risk of hemoptysis, for patients with severe hepatic or renal insufficiency, and for pregnant and lactating women.